Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets

Gege Li, Fangfang Li, Yang Tang, Siyu Guo, Yihan Yao, Fang Yuan, Bicheng Zhang, Yu Jiang, Jing Wang, Dang Wu, Jianxia Cheng, Zhihui Huang, Zengfeng Xin, Ting ZhangMedComm 2025 · DOI

TL;DR

This review highlights the crucial role of neurotransmitters beyond the central nervous system, emphasizing their function as key regulators of systemic homeostasis and their intricate interactions with the immune system. It provides a comprehensive overview of how these molecules influence diseases like cancer, neurodegenerative disorders, and inflammatory conditions, offering a framework for developing targeted therapies.

What Problem Does This Paper Address?

For a long time, neurotransmitters were thought to be confined to the central nervous system (CNS), primarily involved in functions like movement, cognition, and emotion. However, recent research has revealed that they are also produced and secreted in peripheral tissues and by immune cells. This discovery has opened up a new understanding of how the nervous, immune, and metabolic systems are interconnected, forming a "neurotransmitter-immune axis." This axis plays a critical role in the development and progression of various diseases, but our understanding of its complex, context-dependent mechanisms and therapeutic potential has been fragmented. This paper aims to bridge this gap by providing a unified, cross-disciplinary synthesis of neurotransmitter functions across different diseases and their implications for therapeutic strategies.

Methods

This paper is a comprehensive review, not an experimental study. It synthesizes existing research by:

  • Systematically reviewing fundamental properties: It details the biosynthesis, receptor subtypes, and signaling pathways of major neurotransmitters.
  • Analyzing context-dependent roles: It examines how neurotransmitters influence cancer, neurodegenerative diseases (NDDs), and inflammatory disorders, considering factors like receptor type, cellular microenvironment, and disease stage.
  • Evaluating therapeutic approaches: It discusses current and emerging therapies targeting neurotransmitter pathways, including receptor-specific drugs and combination therapies.
  • Identifying clinical translation challenges: It highlights issues like off-target effects and variable efficacy.

Datasets

Not discussed in the paper. This is a review article synthesizing existing literature.

Key Insights and Ideas

  • Neurotransmitters are systemic communicators: They are not just brain chemicals but crucial players in the intricate crosstalk between the nervous, immune, and metabolic systems.
  • The "Neurotransmitter-Immune Axis" is central to disease: This axis is a key regulator of homeostasis and profoundly influences the development of cancer, NDDs, and inflammatory disorders.
  • Context is king: The effect of a neurotransmitter is not fixed; it depends heavily on the specific receptor it binds to, the surrounding cellular microenvironment, and the stage of the disease. This explains why neurotransmitters can have seemingly contradictory effects.
  • Bidirectional roles in disease: Neurotransmitters can both promote and inhibit disease processes, making them complex but promising therapeutic targets.
  • Beyond single targets: Future therapies need to move beyond targeting single neurotransmitters or pathways and embrace a more integrated, multisystem approach.

Key Results

The paper doesn't present new experimental results but synthesizes findings across a vast body of research. Key insights include:

  • Acetylcholine (ACh): Plays dual roles in cancer (promoting proliferation/metastasis in some, inhibiting in others), is implicated in NDDs (cholinergic deficiency in AD, complex roles in PD), and has opposing effects in inflammatory diseases (worsens asthma, alleviates IBD).
  • Epinephrine (EPI) and Norepinephrine (NE): Influence cancer progression (promoting in some, inhibiting in others), contribute to NDDs (locus coeruleus degeneration in PD/AD), and modulate immune evasion in tumors.
  • Serotonin (5-HT): Promotes proliferation and migration in various cancers, is linked to NDDs (deficiency in PD, altered roles in AD), and has complex roles in IBD.
  • Histamine: Exhibits varied effects in cancer (tumor-promoting or inhibiting depending on receptor/cell type), is indirectly involved in PD, and is a core inflammatory mediator in asthma.
  • Dopamine (DA): Has tumor-specific effects on proliferation and metastasis, is central to NDDs (PD, AD), and plays a complex role in IBD pathogenesis.
  • Glutamate: Crucial for cell growth in cancer, drives NDDs through excitotoxicity, and is implicated in IBD pathogenesis.
  • GABA: Exhibits cancer-specific effects on proliferation and metastasis, is universally dysregulated in PD, and contributes to AD pathology.
  • Neuropeptides (SP, NPY, CGRP): Play roles in cancer progression and metastasis, have neuroprotective effects in NDDs, and are involved in inflammatory diseases like asthma and IBD.

Limitations and Future Work

  • Fragmented understanding: Despite advances, the context-dependent nature of neurotransmitter actions leads to a fragmented understanding of their precise roles in disease.
  • Clinical translation challenges: Off-target effects of nonspecific drugs and variable efficacy across disease types remain significant hurdles for therapeutic development.
  • Need for precision: Future research must focus on precisely targeting receptor subtypes and understanding the complex crosstalk between neurotransmitter networks and immune cells.
  • Multisystem coordination: Therapeutic strategies need to move beyond single-target approaches to embrace multisystem coordination and personalized medicine.
  • Advanced drug delivery: Developing targeted drug delivery systems that can overcome physiological barriers (like the BBB) and reach specific cell types is crucial.
  • "Symptom management" vs. "cure": Current interventions often focus on symptom relief rather than addressing the root cause of diseases, highlighting the need for disease-modifying therapies.

Summary updated

Abstract

Traditionally considered to function solely as signaling molecules within the central nervous system (CNS), neurotransmitters are now recognized as key regulators of systemic homeostasis. They modulate interactions among the nervous, immune, and metabolic systems and influence the development of various diseases. This review systematically summarizes the fundamental properties of major neurotransmitters, including their biosynthesis, receptor subtypes, and key signaling pathways, and analyzes their context-dependent roles in cancer, neurodegenerative diseases (NDDs), and inflammatory disorders. A primary focus is the three-dimensional regulatory principle that determines their effects, namely: the receptor type they bind to, cellular microenvironment, and stage of the disease. These factors explain the bidirectional effects of neurotransmitters in disease. This review also evaluates current therapeutic approaches targeting neurotransmitter pathways, ranging from receptor-specific drugs to emerging combination therapies, and discusses challenges in clinical translation, such as off-target effects of nonspecific drugs and variable efficacy across disease types. By linking the fundamental mechanisms of neurotransmitter function to clinical challenges, this review provides a comprehensive framework for exploiting the neurotransmitter-immune axis to develop precise therapeutic strategies aimed at improving outcomes in cancer, NDDs, and inflammatory disorders.
BibTeX
@inproceedings{li2025neurotransmitters,
  author = {Gege Li and Fangfang Li and Yang Tang and Siyu Guo and Yihan Yao and Fang Yuan and Bicheng Zhang and Yu Jiang and Jing Wang and Dang Wu and Jianxia Cheng and Zhihui Huang and Zengfeng Xin and Ting Zhang},
  title = {{Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets}},
  booktitle = {MedComm},
  year = {2025},
  doi = {10.1002/mco2.70556},
}
Figure